The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 15, 2022

Filed:

Oct. 04, 2021
Applicant:

Crispr Therapeutics Ag, Zug, CH;

Inventors:

Mary-Lee Dequeant, Cambridge, MA (US);

Demetrios Kalaitzidis, Cambridge, MA (US);

Mohammed Ghonime, Cambridge, MA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); C07K 14/705 (2006.01); C12N 5/0783 (2010.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 5/16 (2006.01); C12N 15/113 (2010.01); C12N 15/86 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70575 (2013.01); C07K 14/70578 (2013.01); C07K 14/70596 (2013.01); C07K 16/2803 (2013.01); C07K 16/2875 (2013.01); C07K 16/2878 (2013.01); C12N 5/0636 (2013.01); C12N 5/16 (2013.01); C12N 9/22 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); C07K 2317/622 (2013.01); C12N 2310/20 (2017.05); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2510/00 (2013.01);
Abstract

A population of genetically engineered T cells, comprising a disrupted Reg1 gene and/or a disrupted TGFBRII gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; and (c) reduced T cell exhaustion, (d) enhanced cytotoxicity activity, (e) resistant to inhibitory effects induced by TGF-b, and (f) resistant to inhibitory effects by fibroblasts and/or inhibitory factors secreted thereby, as compared to non-engineered T cell counterparts.


Find Patent Forward Citations

Loading…